FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: XORTX Therapeutics Inc. (the "Issuer").

Trading Symbol: XRX

Number of Outstanding Listed Securities: 62,919,691 (as at January 31, 2018)

Date: February 5, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   The Issuer is developing a highly de-risked proprietary, reformulated xanthine oxidase inhibitor (XOI) for the treatment of orphan diseases as well as new XOI's for more common diseases. XOI's are a FDA approved class of drugs with a well known clinical safety profile, although are currently on approved for use in the treatment of gout, evidence suggests a much broader role should be pioneered.

   The primary development program for XORTX is at the clinical stage and is focused on demonstrating first-in-class therapy for autosomal dominant polycystic kidney disease ("ADPKD"), an orphan disease. XORTX has a second, clinical stage program that is currently evaluating two new chemical entities for the treatment of type 2 diabetic nephropathy ("T2DN").

   XORTX intends to grow its business by completing two phase II clinical trials in ADPKD and T2DN, and out-licensing these post-phase II programs. In addition, XORTX plans to grow by expanding our knowledge and technical expertise into new programs to treat orphan progressive kidney disease, fatty liver disease, and health issues related to diabetes. XORTX's overall strategic goal is to have two phase II trials underway within 14 months, advancing two proprietary products into scientifically rigorous phase II testing.

2. Provide a general overview and discussion of the activities of management.

   Management continues the planning for submission submit of an an IND for Submit an IND to advance its ADPKD program into phase II trials within 10 months and receive 'orphan designation' for this program.

Management is also involved in ongoing discussions with a number of specialty pharmaceutical companies from varied jurisdictions with respect to partnering of the ADPKD program once phase II clinical trial data is complete.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   No new products or services developed or offered.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   None.

8. Describe the acquisition of new customers or loss of customers.

   None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There are no identified market trends that are expected to impact the Issuer. The Issuer continues to monitor research and development related to kidney diseases.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 5, 2018.

John Meekison
Name of Director or Senior Officer

"John Meekison"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer XORTX Therapeutics Inc.	For Month End January 2018	Date of Report YY/MM/D February 5, 2018
Issuer Address 2400-745 Thurlow Street		
City/Province/Postal Code Vancouver BC, V6E 0C5	Issuer Fax No. (403) 260-3501	Issuer Telephone No. (403) 607 2621
Contact Name John Meekison	Contact Position CFO	Contact Telephone No. 604-649-8778
Contact Email Address wjmeekison@gmail.com	Web Site Address www.xortx.com	